Control Theory Offers a New Mathematical Map for Safer Aging Drug Discovery

Aging research has catalogued an impressive list of biological culprits over the past decades, from senescent cells and mitochondrial dysfunction to chronic inflammation, epigenetic drift and the gradual collapse of protein quality control. Yet a paper published in Volume 18 of the journal Aging on September 16, 2026 argues that knowing what changes with age is not the same as knowing what to do about it. The study, titled “Control theory of aging and longevity for gerotherapeutic drug discovery: state space, vector fields, modalities, safety, and the minimum safe cost of functional restoration,” introduces a mathematical framework borrowed from engineering that reframes aging not as a list of defects but as a problem of steering a dynamic system safely back toward healthy function.

The work was led by Alex Zhavoronkov, a member of the Aging editorial board who is affiliated with Insilico Medicine and the Buck Institute for Research on Aging. Its starting observation is blunt: established frameworks such as the Hallmarks of Aging and Mikhail Blagosklonny’s hyperfunction theory explain mechanisms of decline, but they do not prescribe how, when or whether those mechanisms should be targeted therapeutically. “Existing aging theories describe what changes with age but do not prescribe how to intervene,” the authors write. Control theory, the mathematical discipline concerned with directing dynamic systems toward desired states, offers precisely that prescriptive language.

At the heart of the framework lies the concept of a biological state space, a multidimensional representation of an organism’s condition spanning inflammation, mitochondrial function, epigenetic stability, immune competence and regenerative capacity. Rather than attempting to rewind every molecular feature to a youthful value, the framework prioritizes maintaining or recovering acceptable physiological function. The authors define a functional viability region, the set of biological states in which essential functions remain within acceptable limits, surrounded by a wider recovery region from which safe interventions could potentially restore function. As aging progresses, this recoverable territory may shrink, making functional restoration progressively harder and eventually impossible.

From this geometry follows a striking redefinition of two familiar concepts. Aging, in this framework, is a progressive loss of safe controllability, and biological age is interpreted not as a molecular signature but as the minimum safe cost required to restore or maintain function. This distinguishes the approach from conventional biological aging clocks, which generally estimate chronological age or health-related risk from molecular measurements. Here, the measure of age is practical: how difficult would it be, with the interventions actually available, to achieve meaningful functional improvement without pushing the system into a dangerous state?

Drugs enter the mathematics as vector fields, meaning mathematical descriptions of how an intervention changes a biological system’s trajectory through state space. Because a vector field depends on the current state, the same treatment can push one patient toward recovery and another toward harm. Treatment effects therefore depend on biological state, dose, duration and tissue conditions rather than being universally beneficial. The authors argue that this formulation could help explain why individuals of similar chronological age may respond so differently to the same intervention, a persistent puzzle in geriatric medicine and in trials of aging-related therapeutics.

The framework also delivers a formal account of why treatment order matters. Using mathematical objects known as Lie brackets, which capture how the composition of two influences depends on the sequence in which they are applied, the authors propose that administering two interventions in different sequences can produce different biological effects even when the same therapies are used. To demonstrate the principle, they built a five-variable computational model of an aged mouse liver incorporating senescent-cell burden, oxidative damage, epigenetic integrity, regenerative capacity and fibrosis, and compared three hypothetical strategies: senolytic treatment followed by partial cellular reprogramming, the reverse sequence, and simultaneous administration.

In the illustrative 56-day simulation, senolytic treatment before reprogramming produced the most favorable modeled outcome, with the proposed explanation that clearing senescent cells first creates conditions that improve subsequent reprogramming. The authors are careful about what this proves. These findings came from mathematical simulations rather than animal experiments, and the predicted benefits of treatment sequencing require biological validation before any clinical conclusions can be drawn. The value of the exercise lies in showing that sequencing effects, often treated as anecdotal, can be made explicit, testable predictions within a rigorous formal structure.

Safety occupies the center of the framework rather than its periphery. “Safety is not a secondary penalty appended after efficacy; it is the central constraint that defines the admissible control set,” the authors write. They distinguish between reversible interventions, such as many small-molecule treatments, and potentially durable approaches including gene editing, viral gene delivery and certain cell therapies. Under the framework, reversible interventions are prioritized when uncertainty is high, while longer-lasting therapies are considered only when their expected benefits and safety are sufficiently supported. The approach also acknowledges hard biological boundaries: extensive fibrosis or irreversible cell loss may mark points beyond which available treatments can no longer restore normal function, underscoring the potential importance of intervention timing and of preventive strategies over late-stage rescue attempts.

To explore clinical relevance, the researchers outlined three translational case studies covering immune aging, age-related muscle loss and ovarian aging, illustrating how intervention selection could account for tissue-specific changes, functional goals and safety constraints. A recurring theme is that molecular proxies can mislead: increasing muscle mass, for example, would not constitute successful treatment if strength, mobility and metabolic function remained impaired. The paper also applies an exploratory scoring framework to aging-related interventions across five biological stages, drawing on aging research databases, clinical trials and therapeutic-target resources, and evaluating treatments by biological coverage, safety, reversibility, durability and potential functional benefits. In this exercise, caloric restriction and aerobic exercise ranked highest, followed by the SGLT2 inhibitors dapagliflozin and empagliflozin, with GLP-1 receptor agonists including liraglutide and semaglutide also scoring relatively high. The authors stress that these scores depend on the framework’s assumptions and weighting criteria and do not demonstrate that any of these drugs extend human lifespan or should be prescribed specifically to treat aging.

Looking forward, the paper sketches a proposed computational system that would integrate molecular measurements, clinical data, mathematical modeling and repeated monitoring to estimate biological states and adjust interventions over time, an approach that could eventually support individualized therapeutic decisions, although a fully trained and experimentally validated implementation does not yet exist. The authors also present 20 falsifiable predictions for future investigation, including whether treatment sequencing influences functional restoration, whether biological states predict individual responses, and whether safety-constrained strategies outperform approaches based mainly on aging biomarkers or single molecular targets. The limitations are acknowledged plainly: biological states cannot be measured completely, the models rest on assumptions requiring experimental validation, the rankings depend on chosen scoring criteria, and the framework’s advantages have not been demonstrated in prospective studies. What the paper offers, ultimately, is a shift in attention for aging drug discovery, away from cataloguing age-related changes and toward determining how function might be restored safely, delivered as a set of testable principles that independent laboratories can now begin to challenge.

Subject of Research: A control theory framework for aging biology and safer gerotherapeutic drug discovery

Article Title: New control theory framework proposes a safer approach to aging drug discovery

Article References: New control theory framework proposes a safer approach to aging drug discovery. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: aging, control theory, gerotherapeutics, drug discovery, biological age, senolytics, cellular reprogramming, state space, vector fields, safety, caloric restriction, SGLT2 inhibitors